Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QLS32015 + pomalidomide + QL2109 + daratumumab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy composed of QLS32015, pomalidomide, QL2109, and daratumumab, studied for the treatment of relapsed or refractory multiple myeloma. QLS32015 is a novel agent administered subcutaneously; pomalidomide is an immunomodulatory drug; QL2109 is a biosimilar of daratumumab, which targets the CD38 antigen on plasma cells; daratumumab is a monoclonal antibody that targets CD38. QL2109 and daratumumab are functionally similar, as both bind to CD38 to induce cell death in myeloma cells[1][3][6].
- Other names
- daratumumabQLS32015QLS-32015QLS 32015QL2109QL-2109QL 2109pomalidomide
02
Targets
CD38 (Cluster of Differentiation 38)CD3 (T-cell surface glycoprotein CD3)GPRC5D
Beyond the preview
Go deeper on QLS32015 + pomalidomide + QL2109 + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLS32015 + pomalidomide + QL2109 + daratumumab.